Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

Simply Wall St.12-15

Bio-Techne Corporation's (NASDAQ:TECH) price-to-earnings (or "P/E") ratio of 79.8x might make it look like a strong sell right now compared to the market in the United States, where around half of the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491050128?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2024-12-15 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491050128","market":"sg","top_or_hot":-1,"title":"Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price","media":"Simply Wall St.","content":"<div>\n<p>Bio-Techne Corporation's (NASDAQ:TECH) price-to-earnings (or \"P/E\") ratio of 79.8x might make it look like a strong sell right now compared to the market in the United States, where around half of the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/why-were-not-concerned-about-bio-techne-corporations-nasdaqt\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-15 22:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/why-were-not-concerned-about-bio-techne-corporations-nasdaqt><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bio-Techne Corporation's (NASDAQ:TECH) price-to-earnings (or \"P/E\") ratio of 79.8x might make it look like a strong sell right now compared to the market in the United States, where around half of the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/why-were-not-concerned-about-bio-techne-corporations-nasdaqt\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/why-were-not-concerned-about-bio-techne-corporations-nasdaqt","article_id":"2491050128","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491050128","pubTimestamp":1734271917,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or \"P/E\") ratio of 79.8x might make it look like a strong...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","TECH":"Techne Corporation","QID":"纳指两倍做空ETF","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4121":"生命科学工具和服务","NDAQ":"纳斯达克OMX交易所","TQQQ":"纳指三倍做多ETF","BK4588":"碎股","USJW.SI":"ALPHAB 3xLongSG261006","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","NVIW.SI":"NVDA 3xLongSG261006","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD",".IXIC":"NASDAQ Composite","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SQQQ":"纳指三倍做空ETF","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","USAW.SI":"AMZN 3xLongSG261006","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"为什么我们不担心Bio-Techne Corporation（纳斯达克：TECH）的股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1,"NDAQ":1,".IXIC":1,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Bio-Techne Corporation's (NASDAQ:TECH) price-to-earnings (or \"P/E\") ratio of 79.8x might make it look like a strong sell right now compared to the market in the United States, where around half of the companies have P/E ratios below 19x and even P/E's below 11x are quite common.  Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.     Bio-Techne could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth.   One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner.  You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.     Check out our latest analysis for Bio-Techne NasdaqGS:TECH Price to Earnings Ratio vs Industry December 15th 2024 Want the full picture on analyst estimates for the company? Then our free report on Bio-Techne will help you uncover what's on the horizon.   How Is Bio-Techne's Growth Trending?   In order to justify its P/E ratio, Bio-Techne would need to produce outstanding growth well in excess of the market.   If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 39%.   As a result, earnings from three years ago have also fallen 16% overall.  Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.     Turning to the outlook, the next three years should generate growth of 28%  per year as estimated by the analysts watching the company.  With the market only predicted to deliver 11% per year, the company is positioned for a stronger earnings result.  In light of this, it's understandable that Bio-Techne's P/E sits above the majority of other companies.  It seems most investors are expecting this strong future growth and are willing to pay more for the stock.    The Key Takeaway  Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.  We've established that Bio-Techne maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected.  Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat.  It's hard to see the share price falling strongly in the near future under these circumstances.      Plus, you should also learn about these   2 warning signs we've spotted with Bio-Techne.  You might be able to find a better investment than Bio-Techne. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings). Valuation is complex, but we're here to simplify it.Discover if Bio-Techne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491050128"}